HeartSciences Inc. has announced a significant merger with Fortitude Mining Holdings, marking a pivotal moment for the company and its strategic direction. This all-stock transaction is set to combine HeartSciences' AI-powered medical technology with Fortitude's focus on digital asset mining, potentially reshaping the competitive landscape in the finance services sector.
HeartSciences, which trades under the ticker HSCS on Nasdaq, is known for its innovative approach to medical technology, leveraging artificial intelligence to enhance patient care. The merger with Fortitude, a vertically integrated digital asset mining platform, signifies a bold move towards diversifying its business model and tapping into the burgeoning digital asset market.
Background
HeartSciences Inc., incorporated in Texas, operates within the finance services sector (SIC 6199). The company has been actively filing with the SEC, with its most recent filings including a definitive proxy statement on October 19, 2026, and a series of additional materials leading up to the merger announcement. The company previously operated under the name Heart Test Laboratories, Inc. until a name change in 2009.
What the Filing Says
The recent SEC filing, dated October 29, 2026, outlines the definitive merger agreement between HeartSciences and Fortitude Mining Holdings. The filing notes, "Fortitude and HeartSciences have entered into a definitive merger agreement to combine in an all-stock transaction." This merger aims to create a robust entity that capitalizes on the strengths of both companies in their respective fields.
Impact
This merger may significantly impact shareholders of HeartSciences as they will need to vote on the proposed transaction. The integration of HeartSciences' medical technology capabilities with Fortitude's digital asset mining operations could lead to innovative developments in both sectors. Stakeholders, including investors and employees, will be closely watching how this merger unfolds and the potential synergies that may arise.
What's Next
The filing does not specify the next steps following the merger announcement. However, it is expected that HeartSciences will continue to provide updates as they prepare for the special meeting where shareholders will vote on the transaction. Investors are urged to read the materials related to the merger as they become available, including the Definitive Proxy Statement and any additional filings with the SEC.
Read Next
Westlake BioPartners Discloses Major Stake in Latigo Biotherapeutics
Westlake BioPartners Acquires Significant Stake in Electra Therapeutics
Coletti Reports New Stock Transactions for Cintas Corp
Bain Capital Life Sciences acquires 9.99% stake in ADC Therapeutics
Studio City International Holdings reports major share transactions
Saba Capital Management acquires shares in New Germany Fund





